Daniel Patschan, Susann Patschan, Igor Matyukhin, Meike Hoffmeister, Martin Lauxmann, Oliver Ritter, Werner Dammermann
Acute kidney injury (AKI) affects increasing numbers of in-hospital patients in Central Europe and the USA, the prognosis remains poor. Although substantial progress has been achieved in the identification of molecular/cellular processes that induce and perpetuate AKI, more integrated pathophysiological perspectives are missing. Metabolomics enables the identification of low-molecular-weight (< 1.5 kD) substances from biological specimens such as certain types of fluid or tissue. The aim of the article was to review the literature on metabolic profiling in experimental AKI and to answer the question if metabolomics allows the integration of distinct pathophysiological events such as tubulopathy and microvasculopathy in ischemic and toxic AKI. The following databases were searched for references: PubMed, Web of Science, Cochrane Library, Scopus. The period lasted from 1940 until 2022. The following terms were utilized: "acute kidney injury" OR "acute renal failure" OR "AKI" AND "metabolomics" OR "metabolic profiling" OR "omics" AND "ischemic" OR "toxic" OR "drug-induced" OR "sepsis" OR "LPS" OR "cisplatin" OR "cardiorenal" OR "CRS" AND "mouse" OR "mice" OR "murine" OR "rats" OR "rat". Additional search terms were "cardiac surgery", "cardiopulmonary bypass", "pig", "dog", and "swine". In total, 13 studies were identified. Five studies were related to ischemic, seven studies to toxic (lipopolysaccharide (LPS), cisplatin), and one study to heat shock-associated AKI. Only one study, related to cisplatin-induced AKI, was performed as a targeted analysis. The majority of the studies identified multiple metabolic deteriorations upon ischemia/the administration of LPS or cisplatin (e.g., amino acid, glucose, lipid metabolism). Particularly, abnormalities in the lipid homeostasis were shown under almost all experimental conditions. LPS-induced AKI most likely depends on the alterations in the tryptophan metabolism. Metabolomics studies provide a deeper understanding of pathophysiological links between distinct processes that are responsible for functional impairment/structural damage in ischemic or toxic or other types of AKI.
急性肾损伤(AKI)影响越来越多的住院患者在中欧和美国,预后仍然很差。尽管在确定诱发和延续AKI的分子/细胞过程方面取得了实质性进展,但缺乏更综合的病理生理观点。代谢组学能够从生物标本(如某些类型的液体或组织)中识别低分子量(< 1.5 kD)物质。本文的目的是回顾关于实验性AKI代谢谱的文献,并回答代谢组学是否允许在缺血性和中毒性AKI中整合不同的病理生理事件,如小管病变和微血管病变。检索了以下数据库:PubMed, Web of Science, Cochrane Library, Scopus。这一时期从1940年持续到2022年。使用了以下术语:“急性肾损伤”或“急性肾功能衰竭”或“AKI”和“代谢组学”或“代谢谱”或“组学”和“缺血”或“毒性”或“药物诱导”或“败血症”或“LPS”或“顺铂”或“心肾”或“CRS”和“小鼠”或“小鼠”或“大鼠”或“大鼠”。其他搜索词包括“心脏手术”、“体外循环”、“猪”、“狗”和“猪”。总共确定了13项研究。五项研究与缺血性有关,七项研究与毒性(脂多糖(LPS),顺铂)有关,一项研究与热休克相关的AKI有关。只有一项与顺铂诱导的AKI相关的研究被作为靶向分析进行。大多数研究发现缺血/给药LPS或顺铂后多种代谢恶化(如氨基酸、葡萄糖、脂质代谢)。特别是,在几乎所有的实验条件下,脂质稳态都表现出异常。lps诱导的AKI很可能与色氨酸代谢的改变有关。代谢组学研究为缺血性、中毒性或其他类型AKI中导致功能损伤/结构损伤的不同过程之间的病理生理联系提供了更深入的了解。
{"title":"Metabolomics in Acute Kidney Injury: The Experimental Perspective.","authors":"Daniel Patschan, Susann Patschan, Igor Matyukhin, Meike Hoffmeister, Martin Lauxmann, Oliver Ritter, Werner Dammermann","doi":"10.14740/jocmr4913","DOIUrl":"https://doi.org/10.14740/jocmr4913","url":null,"abstract":"<p><p>Acute kidney injury (AKI) affects increasing numbers of in-hospital patients in Central Europe and the USA, the prognosis remains poor. Although substantial progress has been achieved in the identification of molecular/cellular processes that induce and perpetuate AKI, more integrated pathophysiological perspectives are missing. Metabolomics enables the identification of low-molecular-weight (< 1.5 kD) substances from biological specimens such as certain types of fluid or tissue. The aim of the article was to review the literature on metabolic profiling in experimental AKI and to answer the question if metabolomics allows the integration of distinct pathophysiological events such as tubulopathy and microvasculopathy in ischemic and toxic AKI. The following databases were searched for references: PubMed, Web of Science, Cochrane Library, Scopus. The period lasted from 1940 until 2022. The following terms were utilized: \"acute kidney injury\" OR \"acute renal failure\" OR \"AKI\" AND \"metabolomics\" OR \"metabolic profiling\" OR \"omics\" AND \"ischemic\" OR \"toxic\" OR \"drug-induced\" OR \"sepsis\" OR \"LPS\" OR \"cisplatin\" OR \"cardiorenal\" OR \"CRS\" AND \"mouse\" OR \"mice\" OR \"murine\" OR \"rats\" OR \"rat\". Additional search terms were \"cardiac surgery\", \"cardiopulmonary bypass\", \"pig\", \"dog\", and \"swine\". In total, 13 studies were identified. Five studies were related to ischemic, seven studies to toxic (lipopolysaccharide (LPS), cisplatin), and one study to heat shock-associated AKI. Only one study, related to cisplatin-induced AKI, was performed as a targeted analysis. The majority of the studies identified multiple metabolic deteriorations upon ischemia/the administration of LPS or cisplatin (e.g., amino acid, glucose, lipid metabolism). Particularly, abnormalities in the lipid homeostasis were shown under almost all experimental conditions. LPS-induced AKI most likely depends on the alterations in the tryptophan metabolism. Metabolomics studies provide a deeper understanding of pathophysiological links between distinct processes that are responsible for functional impairment/structural damage in ischemic or toxic or other types of AKI.</p>","PeriodicalId":15431,"journal":{"name":"Journal of Clinical Medicine Research","volume":"15 6","pages":"283-291"},"PeriodicalIF":0.0,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/07/cd/jocmr-15-283.PMC10332883.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9804801","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-06-01Epub Date: 2023-06-29DOI: 10.14740/jocmr4940
Yelizaveta Medina, Asif Khan, Jonathon Spagnola, James Lafferty
Currently, ivabradine is not approved for the treatment of sinus tachycardia secondary to hyperthyroidism. We aimed to increase the recognition of ivabradine as an effective alternative to, or combination with, beta-blockers in controlling sinus tachycardia secondary to hyperthyroidism. Elevated thyroid hormone levels enhance cardiac performance through a positive chronotropic effect, resulting in an increased heart rate (HR), an effect brought on by increasing the If funny current at sinoatrial node (SAN). Ivabradine is a novel, dose-dependent selective inhibitor of If channels. By decreasing SAN pacemaker activity, ivabradine allows for selective reduction of HR with a resultant increase in ventricular filling time. This mechanism sets ivabradine apart from the typical rate-reducing medications, namely beta-blockers and calcium channel blockers, which simultaneously decrease HR and myocardial contractility. We describe a case of hyperthyroidism-induced sinus tachycardia, resistant to maximal doses of beta-blocker, which was successfully managed by ivabradine. After excluding other causes of tachycardia, such as anemia, hypovolemic states, structural heart disease, drug abuse, and infection, ivabradine was given off-label for symptomatic relief of hyperthyroidism-induced sinus tachycardia. Within 24 h, HR steadily decreased to the low 80s. Our patient had a unique presentation in which he presented with hyperthyroidism-induced sinus tachycardia with no relief after administration of maximal dose of beta-blocker. Ivabradine was then given, with resolution of sinus tachycardia within 24 h.
目前,伊伐布雷定尚未被批准用于治疗甲亢继发的窦性心动过速。我们的目标是让更多人认识到伊伐布雷定可有效替代或联合β-受体阻滞剂控制甲亢继发的窦性心动过速。甲状腺激素水平升高可通过正性时序效应提高心脏性能,从而导致心率(HR)增加,这种效应是通过增加窦房结(SAN)的滑稽电流产生的。伊伐布雷定是一种新型、剂量依赖性的 If 通道选择性抑制剂。通过降低 SAN 起搏器的活性,伊伐布雷定可选择性地降低心率,从而延长心室充盈时间。这种机制使伊伐布雷定有别于典型的降心率药物,即同时降低心率和心肌收缩力的β受体阻滞剂和钙通道阻滞剂。我们描述了一例甲状腺功能亢进引起的窦性心动过速病例,患者对最大剂量的β-受体阻滞剂产生耐药性,伊伐布雷定成功地控制了患者的病情。在排除其他心动过速原因(如贫血、低血容量状态、结构性心脏病、药物滥用和感染)后,患者在标签外使用伊伐布雷定对甲亢诱发的窦性心动过速进行对症缓解。24 小时内,心率稳步下降至 80 多分。我们的患者有一个独特的病例,他出现甲状腺功能亢进诱发的窦性心动过速,服用最大剂量的β-受体阻滞剂后症状仍无缓解。随后他服用了伊伐布雷定,窦性心动过速在 24 小时内得到缓解。
{"title":"Resolution of Sinus Tachycardia Secondary to Hyperthyroidism With Ivabradine.","authors":"Yelizaveta Medina, Asif Khan, Jonathon Spagnola, James Lafferty","doi":"10.14740/jocmr4940","DOIUrl":"10.14740/jocmr4940","url":null,"abstract":"<p><p>Currently, ivabradine is not approved for the treatment of sinus tachycardia secondary to hyperthyroidism. We aimed to increase the recognition of ivabradine as an effective alternative to, or combination with, beta-blockers in controlling sinus tachycardia secondary to hyperthyroidism. Elevated thyroid hormone levels enhance cardiac performance through a positive chronotropic effect, resulting in an increased heart rate (HR), an effect brought on by increasing the <i>I<sub>f</sub></i> funny current at sinoatrial node (SAN). Ivabradine is a novel, dose-dependent selective inhibitor of <i>I<sub>f</sub></i> channels. By decreasing SAN pacemaker activity, ivabradine allows for selective reduction of HR with a resultant increase in ventricular filling time. This mechanism sets ivabradine apart from the typical rate-reducing medications, namely beta-blockers and calcium channel blockers, which simultaneously decrease HR and myocardial contractility. We describe a case of hyperthyroidism-induced sinus tachycardia, resistant to maximal doses of beta-blocker, which was successfully managed by ivabradine. After excluding other causes of tachycardia, such as anemia, hypovolemic states, structural heart disease, drug abuse, and infection, ivabradine was given off-label for symptomatic relief of hyperthyroidism-induced sinus tachycardia. Within 24 h, HR steadily decreased to the low 80s. Our patient had a unique presentation in which he presented with hyperthyroidism-induced sinus tachycardia with no relief after administration of maximal dose of beta-blocker. Ivabradine was then given, with resolution of sinus tachycardia within 24 h.</p>","PeriodicalId":15431,"journal":{"name":"Journal of Clinical Medicine Research","volume":"15 6","pages":"336-339"},"PeriodicalIF":0.0,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/d4/f0/jocmr-15-336.PMC10332879.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9804800","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Background: Pancreatic cancer is gastrointestinal cancer with a poor prognosis. Although surgical techniques and chemotherapy have improved treatment outcomes, the 5-year survival rate for pancreatic cancer is less than 10%. In addition, resection of pancreatic cancer is highly invasive and is associated with high rates of postoperative complications and hospital mortality. The Japanese Pancreatic Association states that preoperative body composition assessment may predict postoperative complications. However, although impaired physical function is also a risk factor, few studies have examined it in combination with body composition. We examined preoperative nutritional status and physical function as risk factors for postoperative complications in pancreatic cancer patients.
Methods: Fifty-nine patients with pancreatic cancer who underwent surgical treatment and were discharged alive from January 1, 2018, to March 31, 2021, at the Japanese Red Cross Medical Center. This retrospective study was conducted using electronic medical records and a database of departments. Body composition and physical function were evaluated before and after surgery, and the risk factors between patients with and without complications were compared.
Results: Fifty-nine patients were analyzed: 14 and 45 patients in the uncomplicated and complicated groups, respectively. The major complications were pancreatic fistulas (33%) and infections (22%). There were significant differences in: age, 74.0 (44 - 88) (P = 0.02); walking speed, 0.93 m/s (0.3 - 2.2) (P = 0.01); and fat mass, 16.50 kg (4.7 - 46.2) (P = 0.02), in the patients with complications. On Multivariable logistic regression analysis, age (odds ratio: 2.28; confidence interval (CI): 1.3400 - 569.00; P = 0.03), preoperative fat mass (odds ratio: 2.28; CI: 1.4900 - 168.00; P = 0.02), and walking speed (odds ratio: 0.119; CI: 0.0134 - 1.07; P = 0.05) were identified as risk factors. Walking speed (odds ratio: 0.119; CI: 0.0134 - 1.07; P = 0.05) was the risk factor that was extracted.
Conclusions: Older age, more preoperative fat mass, and decreased walking speed were possible risk factors for postoperative complications.
{"title":"Preoperative Risk Factors in Patients With Pancreatic Cancer.","authors":"Naomi Kusama, Yuta Mitobe, Natsuko Hyodo, Tetsuya Miyashita, Yasuko Baba, Takuya Hashimoto, Yoshimi Inagaki","doi":"10.14740/jocmr4906","DOIUrl":"https://doi.org/10.14740/jocmr4906","url":null,"abstract":"<p><strong>Background: </strong>Pancreatic cancer is gastrointestinal cancer with a poor prognosis. Although surgical techniques and chemotherapy have improved treatment outcomes, the 5-year survival rate for pancreatic cancer is less than 10%. In addition, resection of pancreatic cancer is highly invasive and is associated with high rates of postoperative complications and hospital mortality. The Japanese Pancreatic Association states that preoperative body composition assessment may predict postoperative complications. However, although impaired physical function is also a risk factor, few studies have examined it in combination with body composition. We examined preoperative nutritional status and physical function as risk factors for postoperative complications in pancreatic cancer patients.</p><p><strong>Methods: </strong>Fifty-nine patients with pancreatic cancer who underwent surgical treatment and were discharged alive from January 1, 2018, to March 31, 2021, at the Japanese Red Cross Medical Center. This retrospective study was conducted using electronic medical records and a database of departments. Body composition and physical function were evaluated before and after surgery, and the risk factors between patients with and without complications were compared.</p><p><strong>Results: </strong>Fifty-nine patients were analyzed: 14 and 45 patients in the uncomplicated and complicated groups, respectively. The major complications were pancreatic fistulas (33%) and infections (22%). There were significant differences in: age, 74.0 (44 - 88) (P = 0.02); walking speed, 0.93 m/s (0.3 - 2.2) (P = 0.01); and fat mass, 16.50 kg (4.7 - 46.2) (P = 0.02), in the patients with complications. On Multivariable logistic regression analysis, age (odds ratio: 2.28; confidence interval (CI): 1.3400 - 569.00; P = 0.03), preoperative fat mass (odds ratio: 2.28; CI: 1.4900 - 168.00; P = 0.02), and walking speed (odds ratio: 0.119; CI: 0.0134 - 1.07; P = 0.05) were identified as risk factors. Walking speed (odds ratio: 0.119; CI: 0.0134 - 1.07; P = 0.05) was the risk factor that was extracted.</p><p><strong>Conclusions: </strong>Older age, more preoperative fat mass, and decreased walking speed were possible risk factors for postoperative complications.</p>","PeriodicalId":15431,"journal":{"name":"Journal of Clinical Medicine Research","volume":"15 6","pages":"300-309"},"PeriodicalIF":0.0,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/0e/42/jocmr-15-300.PMC10332881.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9804796","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Group B streptococcus (GBS) is recognized as the most frequent cause of severe early-onset infection in newborn infants. GBS has been observed to be present in the bowel flora of 17.4% of adults (colonization) including pregnant women, and those who are colonized are called “carriers” [1]. To date, more than half of early-onset GBS disease has been reported to occur in neonates born to women with negative GBS screening tests [2, 3]. For example, the recent article in Japan by Miyata et al [2] has also concerned that early-onset GBS disease can develop in infants who are born to mothers with negative GBS screening results. The timing of GBS screening at 35 37 weeks recommended by the Centers for Disease Control and Prevention (CDC) [4] and the American College of Obstetricians and Gynecologists (ACOG) [5] was established based on an earlier study by Yancey et al [6], which indicated that the accuracy of late antenatal anogenital cultures in predicting GBS colonization at delivery is high in cultures collected at 1 5 weeks before delivery. In their observation, the sensitivity, specificity, positive predictive value, and negative predictive value of GBS cultures at 1 5 weeks before delivery for identifying colonization status at delivery were 87%, 96%, 87%, and 96%, respectively. While they were only 43%, 85%, 50%, and 81%, respectively among patients cultured 6 or more weeks before delivery. In their observation [6], a swab for culture specimen was inserted through the anal sphincter; however, the vaginal-perianal collection method has been indicated to be less painful and comfortable [7]. In some recent examinations [7-9], the detection rates of GBS culture from the (vaginal-) perianal area have been observed to be similar to that of anorectal specimens; however, the accuracy of antenatal screening for GBS with cultures from the perianal area has not been well examined. The protocol for this prospective study was approved by the Ethics Committee of Japanese Red Cross Katsushika Maternity Hospital (K2007-15). Informed consent concerning analysis was obtained from all subjects. We performed maternal GBS culture from perianal area used non-selective enrichment medium in 93 Japanese pregnant women scheduled vaginal delivery with GBS-positive at 35 weeks’ gestation every week until delivery. Of these, 84 (90%) delivered at ≤ 40 weeks’ gestation (within 5 weeks). The clinical characteristics of the 84 women are shown in Table 1. All women received the administration of ampicillin intravenous (IV) during labor or after premature membrane rupture. Fortunately, there were no cases of neonatal infection as shown in Table 1. At 36 weeks’ gestation, 62 of these were defined as GBSpositive (positive predictive value: 74%), while 22 (26%) were negative. At 37 weeks’ gestation, the different results from those of the previous week (36 weeks’ gestation) were defined in 29 (15 + 14: 35%) women as shown in Figure 1. At the last perinatal visits, GBS-positive was d
{"title":"Low Accuracy of Antenatal Screening for Group B Streptococcus From Perianal Area.","authors":"Shunji Suzuki","doi":"10.14740/jocmr4927","DOIUrl":"https://doi.org/10.14740/jocmr4927","url":null,"abstract":"Group B streptococcus (GBS) is recognized as the most frequent cause of severe early-onset infection in newborn infants. GBS has been observed to be present in the bowel flora of 17.4% of adults (colonization) including pregnant women, and those who are colonized are called “carriers” [1]. To date, more than half of early-onset GBS disease has been reported to occur in neonates born to women with negative GBS screening tests [2, 3]. For example, the recent article in Japan by Miyata et al [2] has also concerned that early-onset GBS disease can develop in infants who are born to mothers with negative GBS screening results. The timing of GBS screening at 35 37 weeks recommended by the Centers for Disease Control and Prevention (CDC) [4] and the American College of Obstetricians and Gynecologists (ACOG) [5] was established based on an earlier study by Yancey et al [6], which indicated that the accuracy of late antenatal anogenital cultures in predicting GBS colonization at delivery is high in cultures collected at 1 5 weeks before delivery. In their observation, the sensitivity, specificity, positive predictive value, and negative predictive value of GBS cultures at 1 5 weeks before delivery for identifying colonization status at delivery were 87%, 96%, 87%, and 96%, respectively. While they were only 43%, 85%, 50%, and 81%, respectively among patients cultured 6 or more weeks before delivery. In their observation [6], a swab for culture specimen was inserted through the anal sphincter; however, the vaginal-perianal collection method has been indicated to be less painful and comfortable [7]. In some recent examinations [7-9], the detection rates of GBS culture from the (vaginal-) perianal area have been observed to be similar to that of anorectal specimens; however, the accuracy of antenatal screening for GBS with cultures from the perianal area has not been well examined. The protocol for this prospective study was approved by the Ethics Committee of Japanese Red Cross Katsushika Maternity Hospital (K2007-15). Informed consent concerning analysis was obtained from all subjects. We performed maternal GBS culture from perianal area used non-selective enrichment medium in 93 Japanese pregnant women scheduled vaginal delivery with GBS-positive at 35 weeks’ gestation every week until delivery. Of these, 84 (90%) delivered at ≤ 40 weeks’ gestation (within 5 weeks). The clinical characteristics of the 84 women are shown in Table 1. All women received the administration of ampicillin intravenous (IV) during labor or after premature membrane rupture. Fortunately, there were no cases of neonatal infection as shown in Table 1. At 36 weeks’ gestation, 62 of these were defined as GBSpositive (positive predictive value: 74%), while 22 (26%) were negative. At 37 weeks’ gestation, the different results from those of the previous week (36 weeks’ gestation) were defined in 29 (15 + 14: 35%) women as shown in Figure 1. At the last perinatal visits, GBS-positive was d","PeriodicalId":15431,"journal":{"name":"Journal of Clinical Medicine Research","volume":"15 6","pages":"340-342"},"PeriodicalIF":0.0,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/66/05/jocmr-15-340.PMC10332875.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9804799","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Background: Coronavirus disease 2019 (COVID-19)-related organ dysfunction is increasingly considered as sepsis of viral origin. In recent clinical and autopsy studies, sepsis has been present in the majority of decedents with COVID-19. Given the high mortality toll of COVID-19, sepsis epidemiology would be expected to be substantially transformed. However, the impact of COVID-19 on sepsis-related mortality at the national level has not been quantified. We aimed to estimate the contribution of COVID-19 to sepsis-related mortality in the USA during the first year of the pandemic.
Methods: We used the Centers for Disease Control Wide-Ranging Online Data for Epidemiological Research (CDC WONDER) Multiple Cause of Death dataset to identify decedents with sepsis during 2015 - 2019, and those with a diagnosis of sepsis, COVID-19, or both in 2020. Negative binomial regression was used on the 2015 - 2019 data to forecast the number of sepsis-related deaths in 2020. We then compared the observed vs. predicted number of sepsis-related deaths in 2020. In addition, we examined the frequency of a diagnosis of COVID-19 among decedents with sepsis and the proportion of a diagnosis of sepsis among decedents with COVID-19. The latter analysis was repeated within each of the Department of Health and Human Services (HHS) regions.
Results: In 2020, there were 242,630 sepsis-related deaths, 384,536 COVID-19-related deaths, and 35,807 deaths with both in the USA. The predicted number of sepsis-related deaths for 2020 was 206,549 (95% confidence interval (CI): 201,550 - 211,671). COVID-19 was reported in 14.7% of decedents with sepsis, while a diagnosis of sepsis was reported in 9.3% of all COVID-19-related deaths, ranging from 6.7% to 12.8% across HHS regions.
Conclusions: A diagnosis of COVID-19 was reported in less than one in six of decedents with sepsis in 2020, with corresponding less than one in 10 diagnoses of sepsis among decedents with COVID-19. These findings suggest that death certificate-based data may have substantially underestimated the toll of sepsis-related deaths in the USA during the first year of the pandemic.
{"title":"The Impact of COVID-19 on Sepsis-Related Mortality in the United States.","authors":"Lavi Oud, John Garza","doi":"10.14740/jocmr4937","DOIUrl":"https://doi.org/10.14740/jocmr4937","url":null,"abstract":"<p><strong>Background: </strong>Coronavirus disease 2019 (COVID-19)-related organ dysfunction is increasingly considered as sepsis of viral origin. In recent clinical and autopsy studies, sepsis has been present in the majority of decedents with COVID-19. Given the high mortality toll of COVID-19, sepsis epidemiology would be expected to be substantially transformed. However, the impact of COVID-19 on sepsis-related mortality at the national level has not been quantified. We aimed to estimate the contribution of COVID-19 to sepsis-related mortality in the USA during the first year of the pandemic.</p><p><strong>Methods: </strong>We used the Centers for Disease Control Wide-Ranging Online Data for Epidemiological Research (CDC WONDER) Multiple Cause of Death dataset to identify decedents with sepsis during 2015 - 2019, and those with a diagnosis of sepsis, COVID-19, or both in 2020. Negative binomial regression was used on the 2015 - 2019 data to forecast the number of sepsis-related deaths in 2020. We then compared the observed vs. predicted number of sepsis-related deaths in 2020. In addition, we examined the frequency of a diagnosis of COVID-19 among decedents with sepsis and the proportion of a diagnosis of sepsis among decedents with COVID-19. The latter analysis was repeated within each of the Department of Health and Human Services (HHS) regions.</p><p><strong>Results: </strong>In 2020, there were 242,630 sepsis-related deaths, 384,536 COVID-19-related deaths, and 35,807 deaths with both in the USA. The predicted number of sepsis-related deaths for 2020 was 206,549 (95% confidence interval (CI): 201,550 - 211,671). COVID-19 was reported in 14.7% of decedents with sepsis, while a diagnosis of sepsis was reported in 9.3% of all COVID-19-related deaths, ranging from 6.7% to 12.8% across HHS regions.</p><p><strong>Conclusions: </strong>A diagnosis of COVID-19 was reported in less than one in six of decedents with sepsis in 2020, with corresponding less than one in 10 diagnoses of sepsis among decedents with COVID-19. These findings suggest that death certificate-based data may have substantially underestimated the toll of sepsis-related deaths in the USA during the first year of the pandemic.</p>","PeriodicalId":15431,"journal":{"name":"Journal of Clinical Medicine Research","volume":"15 6","pages":"328-331"},"PeriodicalIF":0.0,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/4b/b7/jocmr-15-328.PMC10332882.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9811861","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Background: The gut microbiome may play an important role in the etiology and progression of colon cancer. The present hypothesis-testing study compared the colon cancer incidence rate among adults diagnosed with intestinal Clostridioides (formerly Clostridium) difficile (Cdiff) (the Cdiff cohort) to adults not diagnosed with intestinal Cdiff infection (the non-Cdiff cohort).
Methods: De-identified eligibility and claim healthcare records within the Independent Healthcare Research Database (IHRD) from a longitudinal cohort of adults (the overall cohort) enrolled in the Florida Medicaid system between 1990 through 2012 were examined. Adults with ≥ 8 outpatient office visits over 8 years of continuous eligibility were examined. There were 964 adults in the Cdiff cohort and 292,136 adults in the non-Cdiff cohort. Frequency and Cox proportional hazards models were utilized.
Results: Colon cancer incidence rate in the non-Cdiff cohort remained relatively uniform over the entire study period, whereas a marked increase was observed in the Cdiff cohort within the first 4 years of a Cdiff diagnosis. Colon cancer incidence was significantly increased (about 2.7-fold) in the Cdiff cohort (3.11 per 1,000 person-years) compared to the non-Cdiff cohort (1.16 per 1,000 person-years). Adjustments for gender, age, residency, birthdate, colonoscopy screening, family history of cancer, and personal history of tobacco abuse, alcohol abuse/dependence, drug abuse/dependence, and overweight/obesity, as well as consideration of diagnostic status for ulcerative and infection colitis, immunodeficiency, and personal history of cancer did not significantly change the observed results.
Conclusions: This is the first epidemiological study associating Cdiff with an increased risk for colon cancer. Future studies should further evaluate this relationship.
{"title":"Colon Cancer Risk Following Intestinal <i>Clostridioides difficile</i> Infection: A Longitudinal Cohort Study.","authors":"David A Geier, Mark R Geier","doi":"10.14740/jocmr4919","DOIUrl":"https://doi.org/10.14740/jocmr4919","url":null,"abstract":"<p><strong>Background: </strong>The gut microbiome may play an important role in the etiology and progression of colon cancer. The present hypothesis-testing study compared the colon cancer incidence rate among adults diagnosed with intestinal <i>Clostridioides</i> (formerly <i>Clostridium) difficile</i> (Cdiff) (the Cdiff cohort) to adults not diagnosed with intestinal Cdiff infection (the non-Cdiff cohort).</p><p><strong>Methods: </strong>De-identified eligibility and claim healthcare records within the Independent Healthcare Research Database (IHRD) from a longitudinal cohort of adults (the overall cohort) enrolled in the Florida Medicaid system between 1990 through 2012 were examined. Adults with ≥ 8 outpatient office visits over 8 years of continuous eligibility were examined. There were 964 adults in the Cdiff cohort and 292,136 adults in the non-Cdiff cohort. Frequency and Cox proportional hazards models were utilized.</p><p><strong>Results: </strong>Colon cancer incidence rate in the non-Cdiff cohort remained relatively uniform over the entire study period, whereas a marked increase was observed in the Cdiff cohort within the first 4 years of a Cdiff diagnosis. Colon cancer incidence was significantly increased (about 2.7-fold) in the Cdiff cohort (3.11 per 1,000 person-years) compared to the non-Cdiff cohort (1.16 per 1,000 person-years). Adjustments for gender, age, residency, birthdate, colonoscopy screening, family history of cancer, and personal history of tobacco abuse, alcohol abuse/dependence, drug abuse/dependence, and overweight/obesity, as well as consideration of diagnostic status for ulcerative and infection colitis, immunodeficiency, and personal history of cancer did not significantly change the observed results.</p><p><strong>Conclusions: </strong>This is the first epidemiological study associating Cdiff with an increased risk for colon cancer. Future studies should further evaluate this relationship.</p>","PeriodicalId":15431,"journal":{"name":"Journal of Clinical Medicine Research","volume":"15 6","pages":"310-320"},"PeriodicalIF":0.0,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/74/7b/jocmr-15-310.PMC10332880.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9814471","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Adalia H Jun-O'Connell, Shravan Sivakumar, Nils Henninger, Brian Silver, Meghna Trivedi, Mehdi Ghasemi, Rakhee R Lalla, Kimiyoshi J Kobayashi
Background: Telestroke is an established telemedicine method of delivering emergency stroke care. However, not all neurological patients utilizing telestroke service require emergency interventions or transfer to a comprehensive stroke center. To develop an understanding of the appropriateness of inter-hospital neurological transfers utilizing the telemedicine, our study aimed to assess the differences in outcomes of inter-hospital transfers utilizing the service in relation to the need for neurological interventions.
Methods: The pragmatic, retrospective analysis included 181 consecutive patients, who were emergently transferred from telestroke-affiliated regional medical centers between October 3, 2021, and May 3, 2022. In this exploratory study investigating the outcomes of telestroke-referred patients, patients receiving interventions were compared to those that did not following transfer to our tertiary center. Neurological interventions included mechanical thrombectomy (MT) and/or tissue plasminogen activator (tPA), craniectomy, electroencephalography (EEG), or external ventricular drain (EVD). Transfer mortality rate, discharge functional status defined by modified Rankin scale (mRS), neurological status defined by National Institutes of Health Stroke Scale (NIHSS), 30-day unpreventable readmission rate, 90-day clinical major adverse cardiovascular events (MACE), and 90-day mRS, and NIHSS were studied. We used χ2 or Fisher exact tests to evaluate the association between the intervention and categorical or dichotomous variables. Continuous or ordinal measures were compared using Wilcoxon rank-sum tests. All tests of statistical significance were considered to be significant at P < 0.05.
Results: Among the 181 transferred patients, 114 (63%) received neuro-intervention and 67 (37%) did not. The death rate during the index admission was not statistically significant between the intervention and non-intervention groups (P = 0.196). The discharge NIHSS and mRS were worse in the intervention compared to the non-intervention (P < 0.05 each, respectively). The 90-day mortality and cardiovascular event rates were similar between intervention and non-intervention groups (P > 0.05 each, respectively). The 30-day readmission rates were also similar between the two groups (14% intervention vs. 13.4% non-intervention, P = 0.910). The 90-day mRS were not significantly different between intervention and non-intervention groups (median 3 (IQR: 1 - 6) vs. 2 (IQR: 0 - 6), P = 0.109). However, 90-day NIHSS was worse in the intervention compared to non-intervention group (median 2 (IQR: 0 - 11) vs. 0 (IQR: 0 - 3), P = 0.004).
Conclusions: Telestroke is a valuable resource that expedites emergent neurological care via referral to a stroke center. However, not all transferred patients benefit from the transfer process. Future multicenter studies are warranted to s
{"title":"Outcomes of Telestroke Inter-Hospital Transfers Among Intervention and Non-Intervention Patients.","authors":"Adalia H Jun-O'Connell, Shravan Sivakumar, Nils Henninger, Brian Silver, Meghna Trivedi, Mehdi Ghasemi, Rakhee R Lalla, Kimiyoshi J Kobayashi","doi":"10.14740/jocmr4945","DOIUrl":"https://doi.org/10.14740/jocmr4945","url":null,"abstract":"<p><strong>Background: </strong>Telestroke is an established telemedicine method of delivering emergency stroke care. However, not all neurological patients utilizing telestroke service require emergency interventions or transfer to a comprehensive stroke center. To develop an understanding of the appropriateness of inter-hospital neurological transfers utilizing the telemedicine, our study aimed to assess the differences in outcomes of inter-hospital transfers utilizing the service in relation to the need for neurological interventions.</p><p><strong>Methods: </strong>The pragmatic, retrospective analysis included 181 consecutive patients, who were emergently transferred from telestroke-affiliated regional medical centers between October 3, 2021, and May 3, 2022. In this exploratory study investigating the outcomes of telestroke-referred patients, patients receiving interventions were compared to those that did not following transfer to our tertiary center. Neurological interventions included mechanical thrombectomy (MT) and/or tissue plasminogen activator (tPA), craniectomy, electroencephalography (EEG), or external ventricular drain (EVD). Transfer mortality rate, discharge functional status defined by modified Rankin scale (mRS), neurological status defined by National Institutes of Health Stroke Scale (NIHSS), 30-day unpreventable readmission rate, 90-day clinical major adverse cardiovascular events (MACE), and 90-day mRS, and NIHSS were studied. We used χ<sup>2</sup> or Fisher exact tests to evaluate the association between the intervention and categorical or dichotomous variables. Continuous or ordinal measures were compared using Wilcoxon rank-sum tests. All tests of statistical significance were considered to be significant at P < 0.05.</p><p><strong>Results: </strong>Among the 181 transferred patients, 114 (63%) received neuro-intervention and 67 (37%) did not. The death rate during the index admission was not statistically significant between the intervention and non-intervention groups (P = 0.196). The discharge NIHSS and mRS were worse in the intervention compared to the non-intervention (P < 0.05 each, respectively). The 90-day mortality and cardiovascular event rates were similar between intervention and non-intervention groups (P > 0.05 each, respectively). The 30-day readmission rates were also similar between the two groups (14% intervention vs. 13.4% non-intervention, P = 0.910). The 90-day mRS were not significantly different between intervention and non-intervention groups (median 3 (IQR: 1 - 6) vs. 2 (IQR: 0 - 6), P = 0.109). However, 90-day NIHSS was worse in the intervention compared to non-intervention group (median 2 (IQR: 0 - 11) vs. 0 (IQR: 0 - 3), P = 0.004).</p><p><strong>Conclusions: </strong>Telestroke is a valuable resource that expedites emergent neurological care via referral to a stroke center. However, not all transferred patients benefit from the transfer process. Future multicenter studies are warranted to s","PeriodicalId":15431,"journal":{"name":"Journal of Clinical Medicine Research","volume":"15 6","pages":"292-299"},"PeriodicalIF":0.0,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/7f/c5/jocmr-15-292.PMC10332878.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10664913","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Acute respiratory distress syndrome (ARDS) is the most common severe pulmonary complication of the coronavirus disease 2019 (COVID-19). Although considered earlier in the pandemic to represent a different clinical entity than nonCOVID-19 ARDS [1], it is nevertheless estimated that ARDS is present in 75% of intensive care unit (ICU) patients with COVID-19 and in 90% of ICU non-survivors [2]. Importantly, autopsy data show that ARDS, as evidenced by findings of diffuse alveolar damage, is present either in all [3] or in the majority of decedents with COVID-19 [4]. The toll of pre-pandemic ARDS-related deaths in the United States was estimated at nearly 10,000/year [5]. With over 375,000 COVID-19-related deaths in the USA during the first year of the pandemic [6], the epidemiology of ARDS was likely transformed substantially [7]. Accurate accounting of the ARDS-related mortality burden during the COVID-19 pandemic can inform future preventive and interventional efforts, as well as health resource allocation. However, the impact of COVID-19 on ARDS-related mortality at a national level has not been quantified. We used the National Center for Health Statistics (NCHS) Multiple Cause of Death data set, which is available through the Centers for Disease Control Wide-ranging Online Data for Epidemiological Research (CDC WONDER) website [8] to obtain mortality and population data. The mortality data in NCHS are based on information from all death certificates filed in the 50 states and the District of Columbia, and provides up to 20 causes of death in addition to an underlying cause of death. We have identified decedents with a diagnosis of ARDS during 2015 2019, and with a diagnosis of COVID-19, ARDS, or both in 2020, listed among any of the 20 causes of death irrespective of the underlying cause of death, which could be ARDS, COVID-19, or other conditions (e.g., cardiovascular disease, etc.). ARDS and COVID-19 were identified by International Classification of Diseases, Tenth Revision, Clinical Modification codes J80 and J071, respectively. Negative binomial regression with log-link and robust standard errors was used on the 2015 2019 data to forecast the number of ARDS-related deaths in 2020. We then compared the number of observed vs. expected ARDS-related deaths in 2020. In addition, we examined the proportion of a diagnosis of COVID-19 among all decedents with a diagnosis of ARDS and reporting of a diagnosis of ARDS among all decedents with a diagnosis of COVID-19. We then repeated the later analysis within each of the Department of Health and Human Services (HHS) Regions. Data analysis was performed using R 4.0.5 (R Foundation for Statistical Computing, Vienna, Austria). The annual ARDS-related mortality and population data for 2015 2020 are detailed in Table 1. In 2020, there were 51,184 ARDS-related deaths, 384,536 COVID-19-related deaths, and 41,606 deaths with both in the USA. The predicted number of ARDS-related deaths for 2020 was 10,851 (95%
{"title":"The Contribution of COVID-19 to Acute Respiratory Distress Syndrome-Related Mortality in the United States.","authors":"Lavi Oud, John Garza","doi":"10.14740/jocmr4915","DOIUrl":"https://doi.org/10.14740/jocmr4915","url":null,"abstract":"Acute respiratory distress syndrome (ARDS) is the most common severe pulmonary complication of the coronavirus disease 2019 (COVID-19). Although considered earlier in the pandemic to represent a different clinical entity than nonCOVID-19 ARDS [1], it is nevertheless estimated that ARDS is present in 75% of intensive care unit (ICU) patients with COVID-19 and in 90% of ICU non-survivors [2]. Importantly, autopsy data show that ARDS, as evidenced by findings of diffuse alveolar damage, is present either in all [3] or in the majority of decedents with COVID-19 [4]. The toll of pre-pandemic ARDS-related deaths in the United States was estimated at nearly 10,000/year [5]. With over 375,000 COVID-19-related deaths in the USA during the first year of the pandemic [6], the epidemiology of ARDS was likely transformed substantially [7]. Accurate accounting of the ARDS-related mortality burden during the COVID-19 pandemic can inform future preventive and interventional efforts, as well as health resource allocation. However, the impact of COVID-19 on ARDS-related mortality at a national level has not been quantified. We used the National Center for Health Statistics (NCHS) Multiple Cause of Death data set, which is available through the Centers for Disease Control Wide-ranging Online Data for Epidemiological Research (CDC WONDER) website [8] to obtain mortality and population data. The mortality data in NCHS are based on information from all death certificates filed in the 50 states and the District of Columbia, and provides up to 20 causes of death in addition to an underlying cause of death. We have identified decedents with a diagnosis of ARDS during 2015 2019, and with a diagnosis of COVID-19, ARDS, or both in 2020, listed among any of the 20 causes of death irrespective of the underlying cause of death, which could be ARDS, COVID-19, or other conditions (e.g., cardiovascular disease, etc.). ARDS and COVID-19 were identified by International Classification of Diseases, Tenth Revision, Clinical Modification codes J80 and J071, respectively. Negative binomial regression with log-link and robust standard errors was used on the 2015 2019 data to forecast the number of ARDS-related deaths in 2020. We then compared the number of observed vs. expected ARDS-related deaths in 2020. In addition, we examined the proportion of a diagnosis of COVID-19 among all decedents with a diagnosis of ARDS and reporting of a diagnosis of ARDS among all decedents with a diagnosis of COVID-19. We then repeated the later analysis within each of the Department of Health and Human Services (HHS) Regions. Data analysis was performed using R 4.0.5 (R Foundation for Statistical Computing, Vienna, Austria). The annual ARDS-related mortality and population data for 2015 2020 are detailed in Table 1. In 2020, there were 51,184 ARDS-related deaths, 384,536 COVID-19-related deaths, and 41,606 deaths with both in the USA. The predicted number of ARDS-related deaths for 2020 was 10,851 (95% ","PeriodicalId":15431,"journal":{"name":"Journal of Clinical Medicine Research","volume":"15 5","pages":"279-281"},"PeriodicalIF":0.0,"publicationDate":"2023-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/ed/80/jocmr-15-279.PMC10251696.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9974798","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Christian Mpody, Onaopepo Kola-Kehinde, Hamdy Awad, Sujatha Bhandary, Michael Essandoh, Demicha Rankin, Antolin Flores, Ronald Harter, Olubukola O Nafiu
Background: Postoperative stroke is a devastating complication of surgery, given its association with severe long-term disability and mortality. Previous investigators have confirmed the association of stroke with postoperative mortality. However, limited data exist regarding the relationship between the timing of stroke and survival. Addressing this knowledge gap will help clinicians develop tailored perioperative strategies to reduce the incidence, severity, and mortality associated with perioperative stroke. Therefore, our objective was to determine whether the timing of postoperative stroke influenced mortality risk.
Methods: We performed a retrospective cohort study of patients > 18 years who underwent noncardiac surgery and developed postoperative stroke during the first 30 days of surgery (National Surgical Quality Improvement Program Pediatrics 2010 - 2021). Our primary outcome was 30-day mortality following the occurrence of postoperative stroke. We subdivided patients into two mutually exclusive groups: early and delayed stroke. Early stroke was defined as the occurrence within 7 days following surgery, consistent with a previous study.
Results: We identified 16,750 patients who underwent noncardiac surgery and developed stroke within 30 days of surgery. Of these, 11,173 (66.7%) had an early postoperative stroke (≤ 7 days). Perioperative physiological status, operative characteristics, and preoperative comorbidities were generally comparable between patients with early and delayed postoperative stroke. Despite the comparability in these clinical characteristics, the mortality risk was 24.9% for early and 19.4% for delayed stroke. After adjusting for perioperative physiological status, operative characteristics, and preoperative comorbidities, early stroke was associated with an increased mortality risk (adjusted odds ratio: 1.39, confidence interval: 1.29 - 1.52, P-value < 0.001). In patients with an early postoperative stroke, the most common preceding complications were bleeding requiring transfusion (24.3%), followed by pneumonia (13.2%) and renal insufficiency (11.3%).
Conclusions: Postoperative stroke tends to occur within 7 days following noncardiac surgery. Such timing of postoperative stroke carries a higher mortality risk, suggesting that targeted efforts to prevent stroke should focus on the first week following surgery to reduce the incidence and mortality associated with this complication. Our findings contribute to the growing understanding of stroke after noncardiac surgery and may help clinicians develop tailored perioperative neuroprotective strategies to prevent or improve treatment and outcomes of postoperative stroke.
{"title":"Timing of Postoperative Stroke and Risk of Mortality After Noncardiac Surgery: A Cohort Study.","authors":"Christian Mpody, Onaopepo Kola-Kehinde, Hamdy Awad, Sujatha Bhandary, Michael Essandoh, Demicha Rankin, Antolin Flores, Ronald Harter, Olubukola O Nafiu","doi":"10.14740/jocmr4877","DOIUrl":"https://doi.org/10.14740/jocmr4877","url":null,"abstract":"<p><strong>Background: </strong>Postoperative stroke is a devastating complication of surgery, given its association with severe long-term disability and mortality. Previous investigators have confirmed the association of stroke with postoperative mortality. However, limited data exist regarding the relationship between the timing of stroke and survival. Addressing this knowledge gap will help clinicians develop tailored perioperative strategies to reduce the incidence, severity, and mortality associated with perioperative stroke. Therefore, our objective was to determine whether the timing of postoperative stroke influenced mortality risk.</p><p><strong>Methods: </strong>We performed a retrospective cohort study of patients > 18 years who underwent noncardiac surgery and developed postoperative stroke during the first 30 days of surgery (National Surgical Quality Improvement Program Pediatrics 2010 - 2021). Our primary outcome was 30-day mortality following the occurrence of postoperative stroke. We subdivided patients into two mutually exclusive groups: early and delayed stroke. Early stroke was defined as the occurrence within 7 days following surgery, consistent with a previous study.</p><p><strong>Results: </strong>We identified 16,750 patients who underwent noncardiac surgery and developed stroke within 30 days of surgery. Of these, 11,173 (66.7%) had an early postoperative stroke (≤ 7 days). Perioperative physiological status, operative characteristics, and preoperative comorbidities were generally comparable between patients with early and delayed postoperative stroke. Despite the comparability in these clinical characteristics, the mortality risk was 24.9% for early and 19.4% for delayed stroke. After adjusting for perioperative physiological status, operative characteristics, and preoperative comorbidities, early stroke was associated with an increased mortality risk (adjusted odds ratio: 1.39, confidence interval: 1.29 - 1.52, P-value < 0.001). In patients with an early postoperative stroke, the most common preceding complications were bleeding requiring transfusion (24.3%), followed by pneumonia (13.2%) and renal insufficiency (11.3%).</p><p><strong>Conclusions: </strong>Postoperative stroke tends to occur within 7 days following noncardiac surgery. Such timing of postoperative stroke carries a higher mortality risk, suggesting that targeted efforts to prevent stroke should focus on the first week following surgery to reduce the incidence and mortality associated with this complication. Our findings contribute to the growing understanding of stroke after noncardiac surgery and may help clinicians develop tailored perioperative neuroprotective strategies to prevent or improve treatment and outcomes of postoperative stroke.</p>","PeriodicalId":15431,"journal":{"name":"Journal of Clinical Medicine Research","volume":"15 5","pages":"268-273"},"PeriodicalIF":0.0,"publicationDate":"2023-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/61/e5/jocmr-15-268.PMC10251695.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9673112","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
It is difficult to identify the causes and optimal treatment of heart failure (HF) in patients with atrial fibrillation (AF) and HF with reduced ejection fraction (EF) (HFrEF). Tachyarrhythmia can cause left ventricular (LV) systolic dysfunction called tachycardia-induced cardiomyopathy (TIC). In patients with TIC, conversion to sinus rhythm may lead to improvement in LV systolic dysfunction. However, it is unclear whether we should try to convert patients with AF without tachycardia to sinus rhythm. A 46-year-old man with chronic AF and HFrEF came to our hospital. His New York Heart Association (NYHA) classification was class II. The blood test showed a brain natriuretic peptide of 105 pg/mL. Electrocardiogram (ECG) and 24-h ECG showed AF without tachycardia. Transthoracic echocardiography (TTE) showed left atrial (LA) dilatation, LV dilatation, and diffuse LV hypokinesis (EF was 40%). Although he was optimized medically, NYHA classification II persisted. Therefore, he underwent direct current cardioversion and catheter ablation. After his AF converted to a sinus rhythm of heart rate (HR) 60 - 70 beats per minute (bpm), TTE showed improvement in LV systolic dysfunction. We gradually reduced oral medications for arrhythmia and HF. We subsequently succeeded in discontinuing all medications 1 year after catheter ablation. TTE performed between 1 and 2 years after catheter ablation showed normal LV function and normal cardiac size. During the 3 years of follow-up, there was no recurrence of AF, and he was not readmitted to the hospital. This patient showed the effectiveness of converting AF to sinus rhythm in patients without tachycardia.
{"title":"A Case of Non-Tachycardic Atrial Fibrillation Whose Left Ventricular Systolic Dysfunction Improved After Catheter Ablation.","authors":"Asami Yamashita, Shunsuke Kiuchi, Takanori Ikeda","doi":"10.14740/jocmr4908","DOIUrl":"https://doi.org/10.14740/jocmr4908","url":null,"abstract":"<p><p>It is difficult to identify the causes and optimal treatment of heart failure (HF) in patients with atrial fibrillation (AF) and HF with reduced ejection fraction (EF) (HFrEF). Tachyarrhythmia can cause left ventricular (LV) systolic dysfunction called tachycardia-induced cardiomyopathy (TIC). In patients with TIC, conversion to sinus rhythm may lead to improvement in LV systolic dysfunction. However, it is unclear whether we should try to convert patients with AF without tachycardia to sinus rhythm. A 46-year-old man with chronic AF and HFrEF came to our hospital. His New York Heart Association (NYHA) classification was class II. The blood test showed a brain natriuretic peptide of 105 pg/mL. Electrocardiogram (ECG) and 24-h ECG showed AF without tachycardia. Transthoracic echocardiography (TTE) showed left atrial (LA) dilatation, LV dilatation, and diffuse LV hypokinesis (EF was 40%). Although he was optimized medically, NYHA classification II persisted. Therefore, he underwent direct current cardioversion and catheter ablation. After his AF converted to a sinus rhythm of heart rate (HR) 60 - 70 beats per minute (bpm), TTE showed improvement in LV systolic dysfunction. We gradually reduced oral medications for arrhythmia and HF. We subsequently succeeded in discontinuing all medications 1 year after catheter ablation. TTE performed between 1 and 2 years after catheter ablation showed normal LV function and normal cardiac size. During the 3 years of follow-up, there was no recurrence of AF, and he was not readmitted to the hospital. This patient showed the effectiveness of converting AF to sinus rhythm in patients without tachycardia.</p>","PeriodicalId":15431,"journal":{"name":"Journal of Clinical Medicine Research","volume":"15 5","pages":"274-278"},"PeriodicalIF":0.0,"publicationDate":"2023-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/de/4d/jocmr-15-274.PMC10251699.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9974799","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}